Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

Royal Marsden NHS Foundation Trust

Status: Unknown

Conditions: Thyroid Carcinoma; Metastatic Sites Lung Bone Nodal

Treatments: Other: SPECT scan

Study type: Interventional

Funder types: Other

Identifiers

NCT00749697

CCR3047

Details and patient eligibility

About

The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.

Full description

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age above 18
• histological confirmation of the differentiated thyroid carcinoma available
• WHO performance score 0-2
• metastatic sites lung and/or bone and/or nodal (radiologically measurable disease > 1 cm)
• life expectancy > 6 months
• patient has undergone total/near total thyroidectomy
• no past history of sensitivity/reaction to 1311

Exclusion criteria

• non iodine concentrating tumours
• received chemotherapy or radiotherapy in 6 weeks
• pregnant or breast feeding patients
• iodine contrast injection in last 3 months

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)